MET and non-small cell lung carcinoma: In contrast, in a panel of five NSCLC cell lines (A549, H460, H3122, H2228, and H1993), crizotinib (c-Met inhibitor), did not significantly mediate cellular radiosensitivity, or altered DNA repair kinetics and even cell cycle distribution; besides it was noted that no consequent delay in tumor growth was observed in response to crizotinib and radiation combination (35).